GlassScriptPhysician profile
Edwin Saji
NPI 1043056963
$1,300.80
in general payments reported to CMS, 2019-2025
12 companies · $862 in 2025
The $862 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $439 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,300.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $308.85 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $307.74 | 2024-2025 | Entyvio |
| Janssen Biotech, INC. | $121.46 | 2025 | Rybrevant, Erleada, Akeega |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.88 | 2024 | |
| Abbott Laboratories | $102.10 | 2024 | Freestyle Libre 3 |
| Actelion Pharmaceuticals US, INC. | $98.95 | 2025 | Uptravi, Opsumit |
| Amgen INC. | $96.05 | 2025 | Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $32.27 | 2024 | |
| Novo Nordisk INC | $31.80 | 2025 | Rybelsus, Ozempic |
| Aimmune Therapeutics, INC. | $28.93 | 2025 | Vowst |
| Alexion Pharmaceuticals, INC. | $28.71 | 2024 | Ultomiris |
| Dexcom, INC. | $23.06 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Saji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.